Persistent Depressive Disorder

Document whether depressed mood has been present most of the day, more days than not, for at least 2 years in adults; in children and adolescents, the required duration is 1 year and mood may be irritable rather than depressed. BMJ+1BMJPersistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best PracticeScienceDirectDysthymia - an overview | ScienceDirect Topics Obtain a timeline rather than relying on the current symptom burden, because PDD may be overlooked until a more severe major depressive episode brings the patient to care. ScienceDirectScienceDirectReview of dysthymia and persistent depressive disorder: history, correlates, and clinical implications

Classify the current longitudinal presentation after confirming chronicity: pure dysthymia without a full major depressive episode during the preceding 2 years; persistent major depressive episode; intermittent major depressive episodes with a current episode; or intermittent major depressive episodes without a current episode. BMJBMJPersistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best Practice This distinction identifies patients with active syndromal major depression versus a chronic subthreshold baseline and frames the immediate treatment target.

Do not equate chronicity with mild illness. PDD is associated with substantial psychosocial impairment, including unemployment, difficulty establishing intimate relationships, increased health care use, and use of public entitlements. BMJBMJPersistent depressive disorder - Prognosis | BMJ Best Practice Assess occupational performance, relationships, self-care, and treatment adherence as outcome domains alongside depressive symptoms.

Perform direct suicide-risk assessment whenever depressive severity worsens, a current major depressive episode is present, treatment is failing, or substance misuse is identified. The precise suicide rate in PDD is unknown, but depression carries substantial suicide risk. BMJBMJPersistent depressive disorder - Prognosis | BMJ Best Practice Escalate urgently according to the patient’s current suicidal intent, planning, ability to maintain safety, and available supports rather than the PDD label alone.

Identify prior adequate psychotherapy and antidepressant exposure before calling symptoms refractory. About 40% of patients with PDD have symptoms considered treatment resistant. BMJBMJPersistent depressive disorder - Prognosis | BMJ Best Practice US For persistent nonresponse, reassess diagnostic course, active anxiety or substance misuse, treatment adherence, adverse effects, and whether the prior treatment was sustained long enough to test benefit.

Late-life presentations warrant attention to medical illness, cognitive deterioration, and recent adverse life events. Compared with younger-onset dysthymia, late-onset dysthymia in older adults has been associated with more comorbid medical illness and cognitive deterioration and fewer depressive-cognition symptoms despite similar neurovegetative and somatic symptoms. Wolters KluwerWolters KluwerClinical Practice Guidelines for Management of... : Indian Journal of Psychiatry A new late-life chronic depressive presentation should therefore prompt assessment of cognitive and medical contributors in parallel with psychiatric treatment.

Offer an evidence-based psychotherapy and/or an antidepressant as first-line treatment modalities for PDD. Antidepressants and psychotherapies are the primary treatments for chronic depressive presentations, although chronic depression may respond less robustly than acute depression. ScienceDirectScienceDirectReview of dysthymia and persistent depressive disorder: history, correlates, and clinical implications Select the initial modality using current severity, previous response, patient preference, access, ability to engage in regular sessions, and the presence of a superimposed major depressive episode.

Consider combined antidepressant medication plus empirically supported psychotherapy when symptoms are chronic, impairing, recurrent, or incompletely responsive to monotherapy. Combination treatment has been described as potentially optimal for chronically depressed patients, and PDD often requires a longer treatment period, more psychotherapy sessions, and/or higher antidepressant doses than acute depression. Oxford Academic+1Oxford Academica CINP Task Force report based on a review of evidenceBMJPersistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best Practice Dose selection and titration should follow the chosen agent’s current prescribing information and patient-specific adverse-effect risks.

For youth, cognitive-behavioral therapy and interpersonal therapy have randomized-trial support, as do SSRIs across child and adolescent depressive disorders. ScienceDirectScienceDirectClinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders Guidance summarized for adolescents supports initial CBT or interpersonal psychotherapy for adolescent depression and fluoxetine as a first-line medication for major depressive disorder; these recommendations may be applied to adolescents with PDD. PubMedPubMedTable 1, Current clinical practice guidelines for the treatment of child and adolescent DDs - Treatment of Depression in Children and Adolescents: A Systematic Review - NCBI Bookshelf In children, evidence was insufficient to recommend psychotherapy or pharmacotherapy over alternatives in the summarized APA guidance. PubMedPubMedTable 1, Current clinical practice guidelines for the treatment of child and adolescent DDs - Treatment of Depression in Children and Adolescents: A Systematic Review - NCBI Bookshelf

Do not substitute unproven complementary agents for established therapy. Acetyl-L-carnitine, amisulpride, DHEA, and testosterone-related strategies have been studied in selected dysthymic populations, but the cited evidence is limited or context-specific; DHEA is described as a third-line complementary and alternative option for mild depression in CANMAT guidance. BMJBMJPersistent depressive disorder - Emerging treatments | BMJ Best Practice These approaches should not displace assessment and treatment of active major depression, suicidality, substance misuse, or anxiety disorders.

Continue treatment after improvement because PDD is defined by chronicity and is frequently complicated by recurrent major depressive episodes. BMJ+1BMJPersistent depressive disorder - Prognosis | BMJ Best Practice USBMJPersistent depressive disorder - Prognosis | BMJ Best Practice In chronic major depression, long-term treatment for 2 to 3 years or longer is likely to reduce relapse. BMJBMJPersistent depressive disorder - Prognosis | BMJ Best Practice US Decide duration jointly after considering recurrence history, residual symptoms, functional recovery, treatment tolerability, and patient preference.

At follow-up, monitor depressive symptoms, emergence of a full major depressive episode, suicidal thinking, functioning, anxiety symptoms, substance use, adherence, and adverse effects. BMJ+3BMJPersistent depressive disorder - Prognosis | BMJ Best Practice USBMJPersistent depressive disorder - Prognosis | BMJ Best PracticeBMJPersistent depressive disorder - Symptoms, diagnosis and treatment | BMJ Best PracticeOxford Academica CINP Task Force report based on a review of evidence Residual baseline symptoms matter because the treatment goal is not only resolution of an acute episode but improvement sufficient that the patient no longer meets dysthymia criteria. BMJBMJPersistent depressive disorder - Prognosis | BMJ Best Practice US

Do not assume monthly interpersonal psychotherapy alone prevents recurrence in older adults. Two late-life depression studies found no recurrence-prevention benefit from monthly interpersonal psychotherapy when combined with either antidepressant medication or placebo, whereas a broader adult major-depression meta-analysis, composed mostly of CBT trials, found reduced relapse risk with psychotherapy. NatureNatureRemission is insufficient: predictors and mechanistic models of recurrence in late-life depression | Neuropsychopharmacology For maintenance psychotherapy, align modality and intensity with the individual’s relapse pattern rather than relying on a fixed monthly IPT schedule.